Sponsored by the AIRR Community

Standardizing the format of a germline set

Germlines
#81

I have made some small updates to the schema definition in response to comments posted in the document:

  • ORCID and PubMed ID added to author name and citation respectively, where these items exist.
  • field labels 5_UTR and LEADIN changed to 5’UTR and L-REGION to match the labels used in the IMGT Ontology, As I noted in the document, I suggest that it is worth using the ontology as a starting point, as the terms are defined and quite widely used. Over time we can adapt and extend the definitions as necessary. The full set of labels is at http://www.imgt.org/ligmdb/label and background/citations are at http://www.imgt.org/IMGTindex/ontology.php .

Does anyone have views on the adoption of the IMGT labels as a starting point?

@a.collins, With respect to the comment in your last mail, the schema can accommodate any other labels we need in addition to the ones we already have (5’UTR, L-REGION, FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4), provided that they are annotations which occur at most once per sequence. If we wanted to add annotations, for example to label hotspots, that can occur multiple times in a sequence, we’d need to construct something else. That’s certainly do-able, but is not going to be easy to read or manage in a spreadsheet-type form.

Are there other labels in addition to the ones listed that we should add at this stage?

What are the copyright issues for IMGT germline sequences?
#82

Actually, on reflection, I think we could handle annotations that could occur multiple times in a sequence fairly easily if we needed to.

#83

Let me first respond to @w.lees, and then I wil try to take up the challenge from @ematsen!

I do think it worth building in the capability to record the recombination signal sequences. And thinking of RSS brings to mind another ‘expansion’ that should probably at least be considered briefly at this stage of the game. All discussion to date has been around IGHV, but the database will eventually have to expand to IGHD and IGHJ. I have no expertise on databases and their design, so my question might be really naive. Does we separately standardize the database format for each gene type? So to articular how my mind wandered from RSS to here, we need 3’ RSS for IGHV, 3’ and 5’ RSS for IGHD and 5’ RSS for IGHJ.

To return to @ematsen’s challenge to potential curators…I don’t think it will be possible to fully present the evidence in favor of a sequence in a database record. As we review the IMGT repertoire, the fact that some evidence is provided in the IMGT database in support of the existence of their named sequences is very helpful, and such evidence is similarly to be found in the VBASE2 database. But the quality of each piece of evidence is only evident after a forensic examination. It will be important that people be able to reasonably easily access information that explains or documents why a sequence is accepted in the way it is. (Such acceptance will probably include a category that are ‘accepted’ as sequences to treat with suspicion.) The rules that guide decision making will have to be very clear, and prominently displayed, but somewhere, submitted sequences will have to be available. @w.lees wrote of publications emerging from the work of the curators, and that is probably also a topic that needs discussing. When new alleles are accepted by the curators, should they report this in a peer-reviewed publication? This might be done once each year, but let’s not forget that this would be a pretty boring task to do, year after year after year. These would not be publications to build a reputation on. So will curators step forward and write such papers, or is another system needed? And of course here we are considering the challenges with a focus that is very much on human sequences, with occasional mentions of mice and macaques. Curating all species will be a mind blowing task if lots of people start cranking out sequences for tens then hundreds then thousands of species.

#84

Thanks @a.collins. Yes we are attempting to define a schema that will cover V, D and J and also B- and T-cell, so we should certainly consider them all.

For the time being I have added V-RS, 3’D-RS, 5’D-RS and J-RS, these being the fields that the IMGT ontology defines for the cases you mention. There are sub-fields as well: for example V-RS is divided into V-HEPTAMER, V-SPACER and V-NONAMER. Altogether, there are >60 descriptive labels in the IMGT ontology, and we may well wish to add to the list over time. I think the important thing, right now, is to make sure we understand the overall principles - for example, that we need a different format for each gene type - and to identify any key fields that we expect people to work with in certain circumstances - for example the FR and CDR fields are key for sequence parsing, and RSS is important to curators.

Let’s suppose that we hold two lists in our system: a list of inferred genes, and a list of original submitted sequences. What information do we want to hold in the system (as opposed to in journal articles, release notes or whatever) regarding the evidence for an inferred gene? At its simplest, this could just be a list of the submitted sequences that are deemed to be evidence. But, from your note, Andrew, it seems to me that we might also want to record some notes explaining why, and some metrics that reflect confidence - the output of the ‘forensic examination’. Perhaps we also want to list submitted sequences which were considered, but were rejected for one reason or another. I’m asking because we need to establish whether we can comfortably fit the supporting evidence into the list of inferred genes. The alternative would be a separate file per inferred gene, holding all the information and notes on supporting sequences, examination, and so on. A condensed list of inferred genes, suitable for use by tools such as parsers, would be assembled from the set of such files.

#85

Thanks for the clarification @w.lees. Some of the group working on evaluation of the existing repertoire and working on ways to incorporate inferred sequences favor a red-orange-green system based upon evidence. I have just sent around a proposal involving 14 rules. I would like to let the group consider my email for a day or two before posting it to B-T.cr. These rules would probably answer some of your questions. I have suggested that inferred sequences would enter at the red level, while all existing IMGT sequences would begin at orange. Many of the IMGT sequences would then be demoted to red, as the rules were applied. The inferred sequences would need to be seen in an accepted proportion of all sequences, in association with different D and J. There would therefore be a set of VDJ sequences that would need to be documented somewhere, to support the decision. As more reports of inferences came in, a sequence could climb from red to orange, and then green. So ultimately three sets of VDJ sequences could be associated with a germline sequence.

In response to one of your points, I have suggested that if a submitted sequence is rejected, it would not be recorded. Hopefully the rules would be sufficiently clear, adn the process sufficiently transparent that virtually all submitted sequences would be accepted.

#86

Yes, please make it useful for the curators :slight_smile: I would expect that the criteria of the germline evaluation group will be able to operationalize the curation process to a large extent. Decisions of a curator that are not covered by / not in line with these rules, will require free text documentation. Right now I do not see a scenario in which this information could not be directly attached to a source or segment (aggregation) record. Therefore the release notes (i.e. free text not in the DB) could be kept to a minimum. Please let me know if I am missing something.

#87

I think I would prefer this.

#88

We also have to think about how these additional features (e.g., RSS, Spacers, etc) factor into our allele calls. At present, there is so little data on these within IMGT, that they tend to have little to no effect on allele names. But there are several examples for which an “allele” in IMGT, say *01 of geneA is associated with more than one RSS. Should these be split into two alleles? Or remain as one allele with an annotation/metadata entry that includes two RSS variants?

#89

I was a bit hesitant whether a requirement for formal publication would be too restrictive, but I agree with your point about creating incentives for publication. So if we assume that publication will be a requirement, what would we count as a publication? Should a manuscript have undergone peer-review and have a PMID or would we also accept stuff that has not undergone formal review but is permanently accessible via a DOI (e.g. bioRxiv or other pre-print servers)?

#90

As a practical matter - this seems to imply that any study annotating a repertoire should cite perhaps 100s of original papers that document the initial observation of each allele used in the database…?

#91

@caschramm I suggest that we create a bibliography as part of an automated report that can be used as Supplementary Information for a paper. This would save quite a bit of time and also perhaps help by defining a standardised format for the detail that should be provided.

#92

Re @caschramm’s query, I would also add that there are times when it would be diifficult and not really helpful to cite references to gene discovery. So a report on a repertoire, with so many genes being used would be one example. But if your repertoire paper had a major focus on IGHV2-5 alleles in the anti-measles response, it might be appropriate to acknowledge the discoverers of those sequences.

#93

Is there a document somewhere summarizing the latest thinking here? Perhaps it can be pinned in this thread?

#94

Here’s a summary of current thinking.

We see a need to store three different kinds of information:

  1. observed sequences
  2. curated germline sets
  3. the detailed information leading to the inclusion or exclusion of a gene from a germline set

At the moment I think we are leaning towards storing this information in three separate kinds of file (and see notes below on observed sequences, which may be stored elsewhere). The use of separate files reflects the different usage and authorship of the three kinds of information. More detailed notes, questions, and current status, below.

1 - Observed Sequences
There is, currently, no suitable public database which will accept inferred sequences, such as germline genes inferred fromrepertoire analysis. Hence we need to create a repository, at least for inferred sequences. I propose that we only accept inferred sequences into this repository, and require gene sequences to be deposited in genbank.

Status - the schema for this file has not been defined as yet.

Questions - Is this approach acceptable? Is it over-simplistic: are there other classes of sequence that we need to consider?

2 - Curated Germline Sets
This is intended to be suitable for use by analysis tools such as IgBLAST, IMGT. It should contain sufficient information for such tools, and should err on the side of being rich without containing excessive information (such as references to all observed sequences contributing evidence) that is unlikely to be needed by the large majority of such tools.

Status - the schema for this file is reasonably mature. Detailed thinking on the current draft is summarised here. More recent work has focussed on refining annotations to be included. I propose that, where it covers annotations that we wish to incorporate, we adopt the IMGT Ontology unless that turns out to give us copyright issues, which I think is unlikely.

Questions - Are we comfortable with the use of the IMGT Ontology? Are there further comments on the schema, or are we ready to declare it complete, at last as a first draft?

3. Detailed curation information on a gene
Having discussed the size and type of this information, I think we are leaning towards creating a file per gene that will reference all observed sequences contributing to its inference, contain such scoring as we agree to incorporate (such as level of confidence in the gene) and so on. There sems to be sufficient depth of information to split it out rather than try to hold this information in the germline set.

Status - the schema for this file has not been defined as yet.

Questions - Are we comfortable with the approach of creating one file per gene to hold this information?

1 Like
#95

Here’s a further question. Are people happy with the level of interaction and discussion on this thread, or do we need a call to discuss some of these points in more depth?

#96

I recently found that there could be a possiblity to provide and annotate such sequences within the DDBJ/EMBL/GenBank database framework, namely as inferential third party annotation (see the last but one point in the “Examples of TPA:inferential” section). It requires that at least one of the sequences has some kind of experimental support, but this should not be a major problem as long as your dataset also contains sequences without SHM.

With “gene sequences” you are referring to sequences for which there is direct experimental evidence?

In general, yes. I do not see any other sequence classes besides “inferred” and “observed”. However, I think we should only create an own primary repository for inferred sequences after all attempts to find a stable solution within the existing database frameworks have failed. Note that this is different from a secondary database that collects and annotates germline segments from different sources as discussed above.

#97

Agree entirely that we shouldn’t create a new primary repository unless we have to. I read through the material you mentioned and the [TPA section] (https://www.ncbi.nlm.nih.gov/genbank/tpa/) of Genbank, and it does look promising. The fundamental limitations, as far as I can see, are that:

  1. all new annotations will be experimentally determined to exist, directly or indirectly (this is a quote from the Genbank manual: I suspect that it applies both to inferred sequences and annotations)
  2. the primary sequences on which the inference is based must be referenced
  3. post submission, but before the sequence is made publicly available in Genbank, it must be described in a peer-reviewed journal.

Inference of sequences from NGS data is not explicitly mentioned, and I suspect may not have been considered when the guidelines were drawn up.

Given the quite strong opinions expressed at the AIRR meeting that Genbank would not accept our inferred germline sequences, I wonder if anyone on the thread has direct experience of trying to submit such sequences?

(Christian, to the question you asked re. “gene sequences”, yes that’s exactly what I meant. Thanks.)

#98

Just to keep the link easily available from this thread, here is a link to the most recent version of @w.lees’ schema.

#99

@martin_corcoran a followup to your suggestion - are you able to provide, or point me to, definitions of the 5’UTR and the leading (L-REGION in IMGT terms) that precisely define their boundaries? I have looked at the IMGT definitions and ontology, but I don’t see any detail.

Many thanks for your help

William

#100

We use a utilitarian approach towards leader and 5’ UTR identification in IgDiscover. We are generally dealing with 5’ RACE data when identifying upstream sequences and we define the leader region as the segment upstream of the V gene up until the furthest upstream ATG between 51 and 69 nucleotides that is in-frame with the V segment.
That seems to work well in a variety of different species.
The 5’ UTR is a little harder to define since it is not easy to get consistent amplification from an exact starting nucleotide using RACE so you end up with a series of sequence lengths of the 5’ UTR.
I’m not sure how we can word this as a concise definition for your table other than say something along the lines of the (consensus?) expressed V gene sequence upstream of the leader sequence.